Factors Affecting Effectiveness of Vaccination Against Hepatitis B Virus in Hemodialysis Patients

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Sep 19

PMID 25232238

Citations 15

Authors

Theodoros Eleftheriadis

Georgios Pissas

Georgia Antoniadi

Vassilios Liakopoulos

Ioannis Stefanidis

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus (HBV) is a major global health problem. Despite the success of the general measures against blood transmitted infections in hemodialysis (HD) units, the prevalence of HBV infection among the HD patients is still high. Thus vaccination against HBV is indicating in this population. However, compared with the general population the seroprotection achieved in HD patients remains relatively low, at about 70%. In this review patient, HD procedure and vaccine-associated factors that affect the efficacy of HBV vaccination are analyzed. Also alternative routes of HBV vaccine administration as well as new and more immunogenic vaccine formulations are discussed. However, besides scientific progress, vigilance of HD physicians and staff regarding the general measures against the transmission of blood borne infections and the vaccination against HBV is also required for reducing the prevalence of this viral infection.

Citing Articles

Knowledge, attitude, and practices toward Hepatitis B infection among hemodialysis patients: A nationwide study in Jordan.

Alaridah N, Jereisat R, Abu-Mutaw S, Abuhani H, Jarrar R, Joudeh R PLoS One. 2024; 19(10):e0312226.

PMID: 39418287 PMC: 11486397. DOI: 10.1371/journal.pone.0312226.

Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030.

Al-Busafi S, Alwassief A Vaccines (Basel). 2024; 12(3).

PMID: 38543922 PMC: 10975970. DOI: 10.3390/vaccines12030288.

Overt and occult hepatitis B virus infection detected among chronic kidney disease patients on haemodialysis at a Tertiary Hospital in Ghana.

Dzudzor B, Nsowah K, Agyemang S, Vento S, Amarh V, Boima V PLoS One. 2024; 19(3):e0290917.

PMID: 38437229 PMC: 10911607. DOI: 10.1371/journal.pone.0290917.

Awareness of Hepatitis B Virus (HBV) Screening Before Marriage and Pregnancy Among Adults in the Al-Baha Region, Saudi Arabia.

Agwa R, Elwan T, Alghamdi H, Alghamdi A, Altaweel F, Alghamdi A Cureus. 2024; 16(1):e52057.

PMID: 38213938 PMC: 10782269. DOI: 10.7759/cureus.52057.

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infections in Hemodialysis Patients at Kano Kidney Center.

Alkhalifah R, Alhaddad M, Alhashem A, Alwesaibi H, AlKhalaf A, Albin Saad A Cureus. 2023; 15(7):e41769.

PMID: 37449288 PMC: 10337696. DOI: 10.7759/cureus.41769.

References

Sennesael J, Van der Niepen P, Verbeelen D . Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int. 1991; 40(1):121-8. DOI: 10.1038/ki.1991.189. View

Favero M, Bond W, Petersen N, Berquist K, MAYNARD J . Detection methods for study of the stability of hepatitis B antigen on surfaces. J Infect Dis. 1974; 129(2):210-2. DOI: 10.1093/infdis/129.2.210. View

Fabrizi F, Dixit V, MARTIN P, Messa P . Hepatitis C virus and the immunological response to hepatitis B virus vaccine in dialysis patients: meta-analysis of clinical studies. J Viral Hepat. 2011; 18(12):871-6. DOI: 10.1111/j.1365-2893.2011.01459.x. View

Moe S, Zekonis M, Harezlak J, Ambrosius W, Gassensmith C, Murphy C . A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis. 2001; 38(4):792-802. DOI: 10.1053/ajkd.2001.27697. View

Betjes M . Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013; 9(5):255-65. DOI: 10.1038/nrneph.2013.44. View

Stachowski J, Pollok M, Barth C, Maciejewski J, Baldamus C . Non-responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. Nephrol Dial Transplant. 1994; 9(2):144-52. View

Fabrizi F, Dixit V, Bunnapradist S, MARTIN P . Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther. 2006; 23(8):1105-12. DOI: 10.1111/j.1365-2036.2006.02877.x. View

Fabrizi F, Dixit V, Martin P, Jadoul M, Messa P . Meta-analysis: the impact of nutritional status on the immune response to hepatitis B virus vaccine in chronic kidney disease. Dig Dis Sci. 2011; 57(5):1366-72. DOI: 10.1007/s10620-011-1987-1. View

Charest A, GrandMaison A, McDougall J, Goldstein M . Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population. Am J Kidney Dis. 2003; 42(6):1193-9. DOI: 10.1053/j.ajkd.2003.08.020. View

10.

Wang C, Sun J, Zhu B, Larsen S, Yu R, Wu J . Hepatitis B virus infection and related factors in hemodialysis patients in China - systematic review and meta-analysis. Ren Fail. 2010; 32(10):1255-64. DOI: 10.3109/0886022X.2010.517354. View

11.

Harnett J, Parfrey P, Kennedy M, Zeldis J, Steinman T, Guttmann R . The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis. 1988; 11(3):210-3. DOI: 10.1016/s0272-6386(88)80151-3. View

12.

Chan T, Fang G, Tang C, Cheng I, Lai K, Ho S . Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002; 36(5):1246-52. DOI: 10.1053/jhep.2002.36156. View

13.

. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001; 50(RR-5):1-43. View

14.

Dede F, Yildiz A, Ayli D, Colak N, Odabas A, Akoglu H . Modulation of the immune response to HBV vaccination by hemodialysis membranes. Int Urol Nephrol. 2009; 42(4):1069-75. DOI: 10.1007/s11255-009-9616-z. View

15.

Kletzmayr J, Watschinger B, Muller C, Demetriou D, Puchhammer-Stockl E, Ferenci P . Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation. 2000; 70(9):1404-7. DOI: 10.1097/00007890-200011150-00024. View

16.

Bertoletti A, Ferrari C . Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2011; 61(12):1754-64. DOI: 10.1136/gutjnl-2011-301073. View

17.

Kamili S, Krawczynski K, McCaustland K, Li X, Alter M . Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007; 28(5):519-24. DOI: 10.1086/513727. View

18.

Fabrizi F, Dixit V, Messa P, MARTIN P . Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients. Aliment Pharmacol Ther. 2010; 32(6):756-62. DOI: 10.1111/j.1365-2036.2010.04410.x. View

19.

Bauer T, Jilg W . Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine. 2005; 24(5):572-7. DOI: 10.1016/j.vaccine.2005.08.058. View

20.

Sari F, Taskapan H . Good response to HBsAg vaccine in dialysis patients is associated with high CD4+/CD8+ ratio. Int Urol Nephrol. 2011; 44(5):1501-6. DOI: 10.1007/s11255-011-0043-6. View